Table 2 Univariate analysis of risk factors associated with CRE carriage

Total length of stay ± SD

48.0 ± 59.5

3.9 ± 3 8

U: 3223

1.266 [1.197–1.340]

(days)

(39.8–56.3)

(3.4–4.5)

(<0.001)

(<0.001)

(moan days 95 % confidence interval)

History of previous overseas hospitalisation

29 (14.3 %)

1 (0.5 %)

28.218 (<0.001)**

33.667 [4.539–259.700]

History of travelling in past 90 days

29 (14.3 %)

15 7.4 %)

4.996 (0.025)*

2.089 [10.83.4.028]

Ambulant on arrival

103 (50.7 %)

153 (75.4 %)

26.432 (<0.001)**

0.337 [0.221–0.513]

Admission to CU

54 (26.6 %)

6 (3.0 %)

45.059 (<0.001)**

11.899 [4.986–28.399]

Mean ICU stay ± SD, day

9.6 ± 12.2

1.2 ± 1.0

U: 46.0 (<0.004)**

-

(mean days 95 % confidence interval)

(6.3—13.0)

(0.1—2.2)

Admission to HD/ICA

106 (52.2 %)

29 (14.3 %)

65.797 (<0.001)**

6.557 [4.057–10.596]

Mean HD/ICA stay ± SD, day

5.3 ± 6.1

2.0 ± 1.7

9.0 (0.372)

-

(mean days 95 % confidence interval)

(4.1–6.5)

(1.4–2.7)

Cardiovascular disease comorbidity

105 (51.7 %)

74 (36.5 %)

9.602 (0.002)**

1.868 [1.256–2.778]

Diabetes mellitus comorbidity

67 (33.0 %)

58 (28.6 %)

0.936 (0.333)

1.232 [0.807–1.870]

Malignancy cormorbidity

57 (28.1 %)

41 (20.2 %)

3.443 (0.064)

1.543 [0.974–2.442]

Immunodeficiency comorbidity

10 (4.9 %)

2 (1.0 %)

5.496 (0.019)*

5.207 [1.126–24.072]

Haematology comorbidity

20 (9.9 %)

5 (2.5 %)

9.591 (0.002)**

4.328 [1.592–11.769]

Exposure to DXT

23 (11.3 %)

11 (5.4 %)

4.622 (0.032)*

2.230 [1.057–4.706]

Exposure to steroid

34 (16.7 %)

12 (5.9 %)

11.866 (0.001)**

3.202 [1.606–6.384]

Exposure to chemotherapy

15 (7.4 %)

16 (7.9 %)

0.035 (0.852)

0.933 [0.448–1.941]

Exposure to penicillin antibiotics

33 (16 3 %)

7 (3.4 %)

18.747 (<0.001)**

5.435 [2.344–12.604]

Exposure to β-lactam/β-lactamase inhibitor combinations antibiotics

122 (60.1 %)

59 (29.1 %)

39.568 (<0.001)**

3.676 [2.432–5.557]

Exposure to cephalosporin antibiotics

65 (32.0 %)

43 (21.2 %)

6.106 (0.013)*

1.753 [1.120–2.742]

Exposure to carbapenems antibiotics

62 (30.5 %)

5 (2.5 %)

58.077 (<0.001)**

17.413 [6.826–44.417]

Exposure to fluoroquinolones antibiotics

35 (17.2 %)

19 (9.4 %)

5.468 (0.019)*

2.018 [1.111–3.663]

Exposure to glycopeptide antibiotics

69 (34.0 %)

4 (2.0 %)

70.564 (<0001)**

25.618 [9.132–71.865]

Exposure to metronidazole antibiotics

36 (17.7 %)

15 (7.4 %)

9.889 (0.002)**

2.702 [1.428–5.110]

Exposure to aminoglycosides antibiotics

17 (8.4 %)

1 (0.5 %)

14.882 (<0.001)**

18.462 [2433–140,097]

Presence of central line device

80 (39.4 %)

11 (5.4 %)

67.433 (<0.001)**

11.353 [5.811–22.179]

Presence of urinary catheter device

86 (42.4 %)

30 (14.8 %)

37.842 (<0.001)**

4.239 [2.630–6.831]

Presence of ETT device

42 (20.7 %)

6 (3.0 %)

30.620 (<0.001)**

8.565 [3.55 1–20.658]

Presence of intra-arterial line device

24 (11.8 %)

5 (2.5 %)

13.406 (<0.001)**

5.309 [1.984–14.2 11]

Presence of drains device

31 (15.3 %)

11 (5.4 %)

10.623 (0.001)**

3.146 [1.534–6.450]

Presence of enteral feeding device

49 (24.1 %)

11 (5.4 %)

28.240 (<0.001)**

5.554 [2.793–11.044]

Presence of additional MRSA

47 (23.2 %)

26 (12.8 %)

7.365 (0.007)**

2.051 [1.213–3.468]

Presence of additional VRE

32 (15.8 %)

5 (2.5 %)

21.678 (<0.001)**

7.411 [2.825-19.441]

Exposure to bronchoscopy procedure

22 (10.8 %)

4 (2.0 %)

13.314 (<0.001)**

6.047 [2.045–17.881]

Exposure to gastroscopy procedure

18 (8.9 %)

10 (4.9 %)

2.455 (0.117)

1.878 [0.845–4.175]

Exposure to colonoscopy procedure

4 (2.0 %)

6 (3.0 %)

0.410 (0.522)

0.660 [0.183–2.375]

Exposure to angiogram procedure

9 (4.4 %)

6 (3.0 %)

0.623 (0.430)

1.523 [0.532–4361]

Underwent surgery

141 (69.5 %)

146 (71.9 %)

0.297 (0.586)

1.126 [0.734–1.727]